Navigation Links
Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
Date:1/30/2008

BEIJING and CLAREMONT, Calif., Jan. 30 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) reports that the volume of bio-enhanced feed products sold during the fourth quarter of 2007 strengthened over the third quarter of 2007 and increased 25% over the same period in the previous year.

Tianjin Kiwa Feed Co., Ltd. ("Kiwa Tianjin") is a joint-venture of Kiwa and Tianjin Challenge Feed Co., Ltd, to engage in developing, manufacturing and marketing of biologically enhanced feed for pigs, chickens, ducks, cows and fish. During 4th quarter of 2007, Kiwa Tianjin sold over 7,600 tons of bio-enhanced feed a 25% increase compared with approximately 6,100 tons during the same period of 2006.

Mr. Wei Li, the Chief Executive Officer of Kiwa stated: "the strong increase in sales shows both the huge potential of China's agricultural markets, and Kiwa's capability to continue to expand its business."

About Kiwa Bio-Tech Products Group Corporation

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC ( http://www.sec.gov ) or visit the Company's website at http://www.kiwabiotech.com .

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward- looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: +1-626-715-5855

Email: kiwabiotech@gmail.com

Robert Schechter

Equity Communications

Tel: +1-212-499-6809

Email: ir4kiwa@hotmail.com


'/>"/>
SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
2. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
3. Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million
4. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
5. Kiwa Bio-Tech Ships 2,700 Tons of Bio-feed in One Month
6. Advanced Bio-Technologies Inc Announces Acquisition by HealthEdge Investment Partners, Tampa FL
7. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
8. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
9. Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million
10. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... ComplianceOnline, the leading governance, risk and compliance advisory network with ... Summit 2017 venue and speaker lineup. The Summit will take place on June 8 ... Omni Parker House Hotel, which is located at 60 School Street, Boston, MA will ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy scientists who ... the company announced that its new round of awards are being given to ...
(Date:3/29/2017)... and NEWARK, Del. , March 29, ... regenerative medicine company, and W. L. Gore ... today announced a collaborative research agreement whereby the two ... therapy delivery device technologies that provide protection from immune ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:3/29/2017)... India , March 29, 2017 The ... to 2022 report is a specialized and comprehensive study on the ... North America , Europe and ... Middle East and Africa ... Browse 172 ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
Breaking Biology News(10 mins):